อาหก

เบาหวานประเภท 1 หรือ ก็จำเป็น ต้องคุมน้ำตาล

โดยเฉพาะ A1C หลายๆ โรงพยาบาลไม่ตรวจเพราะ ราคาแพง

แต่โปรดทราบ สุนัข ที่เป็นเบาหวาน ไป หาสัตว์แพทย์ ก็ได้ตรวจ A1C

ดังนั้น คนชนบท ควรมี สิทธิ ในการตรวจระดับน้ำตาล โดย A1C

ไม่ใช่ได้แค่ ตรวจ FBS ไม่งั้น คนจนๆ อาจ ได้ รับการรักษาเบาหวาน

สู้หมาคนรวยไม่ได้

จากการศึกษาพบว่า A1C ที่ต่ำลง เป้าหมาย น้อยว่า 6.5 -7 %

จะลด ภาวะแทรกซ้อน ทางตา ทางไต และระบบประสาทลงได้ อย่างมีนัยสำคัญ

การให้ ยาฉีดอินซูิลิน จะทำให้ระดับน้ำตาลลดลงได้ดีมากครับ

ต้นฉบับจาก www.medscape.com

The Importance of Getting to Goal

Like type 1 diabetes, type 2 diabetes is marked by persistent hyperglycemia that can lead to a wide range of serious complications, including nephropathy, neuropathy, and retinopathy. An important long-term goal is to maintain glycemic control to decrease the risk of these microvascular complications.1,2

A substantial body of evidence has demonstrated a link to better glycemic control and improved outcomes.1,3 And the link between higher mean hemoglobin A1C levels and microvascular complications are highly significant.3,4

Injectable therapies often become necessary to achieve glycemic goals over the course of the disease.1,2 Patients are concerned with initiating insulin therapy. Many health care professionals report delaying insulin therapy as long as possible. If injectable therapies are required, physicians must inform and motivate patients to the best of their ability.5-7

References

   1. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care. 2006;29(8):1963-1972.

   2. Rodbard HW, Blonde L, Braithwaite SS, et al; AACE Diabetes Mellitus Clinical Practice Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007;13(suppl 1):3-68.

   3. American Diabetes Association. Implications of the United Kingdom Prospective Diabetes Study. Diabetes Care. 2002;25(suppl 1):S28-S32.

   4. Stratton IM, Adler AI, Neil HA, et al, for the United Kingdom Prospective Diabetes Study Group. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405-412.

   5. Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord. 2002;26(suppl 3):S18-S24.

   6. Skovlund SE, Peyrot M, for the Diabetes Attitudes, Wishes, and Needs (DAWN) International Advisory Panel. The Diabetes Attitudes, Wishes, and Needs (DAWN) Program: a new approach to improving outcomes of diabetes care. Diabetes Spectr. 2005;18:136-142.

   7. Data on file. Novo Nordisk Inc., Princeton, NJ.

The Importance of Getting to Goal

Like type 1 diabetes, type 2 diabetes is marked by persistent hyperglycemia that can lead to a wide range of serious complications, including nephropathy, neuropathy, and retinopathy. An important long-term goal is to maintain glycemic control to decrease the risk of these microvascular complications.1,2

A substantial body of evidence has demonstrated a link to better glycemic control and improved outcomes.1,3 And the link between higher mean hemoglobin A1C levels and microvascular complications are highly significant.3,4

Injectable therapies often become necessary to achieve glycemic goals over the course of the disease.1,2 Patients are concerned with initiating insulin therapy. Many health care professionals report delaying insulin therapy as long as possible. If injectable therapies are required, physicians must inform and motivate patients to the best of their ability.5-7

References

   1. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care. 2006;29(8):1963-1972.

   2. Rodbard HW, Blonde L, Braithwaite SS, et al; AACE Diabetes Mellitus Clinical Practice Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007;13(suppl 1):3-68.

   3. American Diabetes Association. Implications of the United Kingdom Prospective Diabetes Study. Diabetes Care. 2002;25(suppl 1):S28-S32.

   4. Stratton IM, Adler AI, Neil HA, et al, for the United Kingdom Prospective Diabetes Study Group. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405-412.

   5. Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord. 2002;26(suppl 3):S18-S24.

   6. Skovlund SE, Peyrot M, for the Diabetes Attitudes, Wishes, and Needs (DAWN) International Advisory Panel. The Diabetes Attitudes, Wishes, and Needs (DAWN) Program: a new approach to improving outcomes of diabetes care. Diabetes Spectr. 2005;18:136-142.

   7. Data on file. Novo Nordisk Inc., Princeton, NJ.